Close Menu

Applied Genomics

Eyeing a commercial launch for Mammostrat in the fourth quarter of this year, Clarient highlighted publication of data further validating the test as “an aid for risk stratifying early stage hormone receptor-treated breast cancer patients."

Clarient Insight Dx Pulmotype is a five-antibody immunohistochemistry test that the company said can be used to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in NSCLC tumor specimens.

Clarient plans to commercialize Applied Genomics' five-antibody immunohistochemistry test for non-small cell lung cancer, called Pulmotype, within its network of pathologists by the first quarter of 2010.

Applied Genomics is gearing up to launch a lung cancer diagnostic panel intended to help physicians make treatment decisions.

Lai Named SVP of R&D at Gen-Probe, Jorge Leon Joins ParagonDx SAB, Strategic Diagnostics Hires Two Execs, and More.

The US has sent its formal notice of withdrawal from the World Health Organization, according to the Wall Street Journal.

Science reports that a draft spending bill would increase the US National Institutes of Health budget by 13 percent.

The Harvard Crimson reports that Harvard and MIT are suing the Department of Homeland Security and ICE over the new international student visa policy.

In Nucleic Acids Research this week: algorithm to determine molecular sequence types and other microbial features, computational method to uncover R-loop structures, and more.